

Carmelo Gurnari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/875351/publications.pdf>

Version: 2024-02-01

90
papers

747
citations

686830

13
h-index

676716

22
g-index

92
all docs

92
docs citations

92
times ranked

769
citing authors

#	ARTICLE	IF	CITATIONS
1	The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. <i>British Journal of Haematology</i> , 2017, 176, 629-636.	1.2	56
2	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. <i>Blood</i> , 2021, 137, 3685-3689.	0.6	50
3	Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. <i>Cell Stem Cell</i> , 2021, 28, 1966-1981.e6.	5.2	49
4	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1885-1895.	0.6	32
5	How I manage acquired pure red cell aplasia in adults. <i>Blood</i> , 2021, 137, 2001-2009.	0.6	29
6	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	0.6	27
7	The emerging role of measurable residual disease detection in AML in morphologic remission. <i>Seminars in Hematology</i> , 2019, 56, 125-130.	1.8	25
8	Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. <i>New England Journal of Medicine</i> , 2022, 386, 1998-2010.	13.9	25
9	Have we reached a molecular era in myelodysplastic syndromes?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 418-427.	0.9	23
10	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. <i>Nature Communications</i> , 2022, 13, 1981.	5.8	23
11	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 865.	1.7	22
12	When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. <i>Chemotherapy</i> , 2019, 64, 238-247.	0.8	19
13	Myeloid lncRNA <i>LOUP</i> mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. <i>Blood</i> , 2021, 138, 1331-1344.	0.6	19
14	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. <i>Cancers</i> , 2020, 12, 1746.	1.7	18
15	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinical biological parameters. <i>British Journal of Haematology</i> , 2021, 193, 129-132.	1.2	17
16	A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. <i>Cells</i> , 2021, 10, 1961.	1.8	16
17	Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 360-363.	1.2	14
18	Applications and efficiency of flow cytometry for leukemia diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1089-1097.	1.5	14

#	ARTICLE	IF	CITATIONS
19	Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. <i>Cancers</i> , 2021, 13, 784.	1.7	14
20	Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. <i>Nature Communications</i> , 2022, 13, 1038.	5.8	13
21	Congenital Rhabdomyosarcoma: a different clinical presentation in two cases. <i>BMC Pediatrics</i> , 2018, 18, 166.	0.7	12
22	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8505.	1.8	12
23	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. <i>JCI Insight</i> , 2021, 6, .	2.3	12
24	Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 642.	1.8	12
25	TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. <i>Blood Advances</i> , 2022, 6, 100-107.	2.5	12
26	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 357.	1.7	11
27	Novel invariant features of Good syndrome. <i>Leukemia</i> , 2021, 35, 1792-1796.	3.3	11
28	Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease. <i>Cancers</i> , 2021, 13, 4418.	1.7	11
29	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	2.8	11
30	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood Cancer Journal</i> , 2021, 11, 187.	2.8	11
31	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. <i>Leukemia</i> , 2021, 35, 2431-2434.	3.3	10
32	Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2802.	1.8	10
33	STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype. <i>Leukemia Research</i> , 2019, 78, 21-23.	0.4	8
34	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102528.	0.6	8
35	Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. <i>IScience</i> , 2022, 25, 103679.	1.9	6
36	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2019, 84, 106191.	0.4	5

#	ARTICLE	IF	CITATIONS
37	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021, 10, 128.	1.3	5
38	The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3135.	1.8	5
39	Copper Deficiency. <i>New England Journal of Medicine</i> , 2021, 385, 640-640.	13.9	5
40	Alternative Splicing in Myeloid Malignancies. <i>Biomedicines</i> , 2021, 9, 1844.	1.4	5
41	Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. <i>Molecular and Clinical Oncology</i> , 2017, 8, 463-465.	0.4	4
42	Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia. <i>Leukemia Research</i> , 2020, 99, 106462.	0.4	4
43	“We cannot paint them all with the same brush”™: the need for a better definition of patients with myelodysplastic syndromes for clinical trial design. <i>British Journal of Haematology</i> , 2022, 196, 268-269.	1.2	4
44	Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
45	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. <i>Hematological Oncology</i> , 2022, , .	0.8	3
46	Aplastic anemia: Quo vadis?. <i>Seminars in Hematology</i> , 2022, 59, 54-55.	1.8	3
47	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.4	2
48	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. <i>British Journal of Haematology</i> , 2019, 186, e100-e103.	1.2	2
49	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021, 35, 3324-3328.	3.3	2
50	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	0.8	2
51	Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria. <i>Lancet, The</i> , 2021, 398, e14.	6.3	2
52	Cell large granular lymphocytic leukemia associated with inclusion body myositis. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 27-28.	0.7	2
53	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 91, 102595.	0.6	2
54	Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience. <i>Blood</i> , 2019, 134, 2150-2150.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Mutant <i>TP53</i> prevents Telomere Shortening in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 375-375.	0.6	2
56	Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 1343-1351.	0.9	2
57	Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. <i>Leukemia</i> , 2022, 36, 2086-2096.	3.3	2
58	Recurrent Sweet's syndrome in a patient with multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1958-1960.	0.2	1
59	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2020, 61, 979-982.	0.6	1
60	Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102549.	0.6	1
61	The Clonal Trajectories of <i>SF3B1</i> Mutations in Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 8-8.	0.6	1
62	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. <i>Blood</i> , 2020, 136, 2-2.	0.6	1
63	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 1-1.	0.6	1
64	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019, 134, 3845-3845.	0.6	1
65	Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML. <i>Blood</i> , 2019, 134, 1458-1458.	0.6	1
66	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 602-602.	0.6	1
67	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. <i>Blood</i> , 2021, 138, 3666-3666.	0.6	1
68	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. <i>Leukemia</i> , 2021, , .	3.3	1
69	Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 603-603.	0.6	1
70	TERT Rare Variants in Myeloid Neoplasia: Lack of Clinical Impact or Role as Risk Alleles. <i>Blood</i> , 2021, 138, 1537-1537.	0.6	1
71	Transcriptomic Profile Identifies Early Signatures of Immunoediting and a Potential Role for VISTA As a Molecular Target in Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4467-4467.	0.6	1
72	The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 28-28.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (donor Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S139.	2.0	0
74	Unravelling Genetic Mechanisms of Erythrocytosis: A Real-Life Experience from a Single Center. <i>Blood</i> , 2018, 132, 3617-3617.	0.6	0
75	Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters. <i>Blood</i> , 2019, 134, 5170-5170.	0.6	0
76	Early detection of IgH monoclonal rearrangement in follicular spicules of the nose preceding multiple myeloma diagnosis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 364-366.	0.8	0
77	What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?. <i>Expert Opinion on Pharmacotherapy</i> , 2021, , 1-6.	0.9	0
78	Is Nature Truly Healing Itself? Spontaneous Remissions and Clonal Replacement in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2021, 138, 4303-4303.	0.6	0
79	Molecular Signatures of Immune Pressure and Immune Escape in Hematological Malignancies. <i>Blood</i> , 2021, 138, 1093-1093.	0.6	0
80	Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 8-8.	0.6	0
81	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. <i>Blood</i> , 2020, 136, 25-25.	0.6	0
82	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
83	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
84	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. <i>Blood</i> , 2020, 136, 28-28.	0.6	0
85	Implication of Piga Genotype on Clinical Features of PNH. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
86	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
87	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
88	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
89	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
90	Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 18-18.	0.6	0